New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
04:55 EDTMDVN, MDVN, MDVN, MYGN, MYGN, MYGNAmerican Society of Clinical Oncology to hold symposium
ASCO 2014 Genitourinary (GU) Cancers Symposium is being held in San Francisco on January 30-February 1.
News For MDVN;MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
09:21 EDTMYGNIridian Asset reports 5.5% passive stake in Myriad Genetics
08:31 EDTMYGNMyriad Genetics guidance at risk, says Morgan Stanley
Subscribe for More Information
07:58 EDTMDVNMedivation price target raised to $128 from $112 at Stifel
After surveying 25 urologists, Stifel believes that MEdivation's (MDVN) Xtandi drug has surpassed its main competitor, Johnson & Johnson's (JNJ) Zytiga, as a treatment of prostate cancer prior to chemotherapy. Stifel keeps a Buy rating on Medivation.
January 26, 2015
07:17 EDTMYGNSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 23, 2015
15:46 EDTMYGNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
10:02 EDTMDVNOn the Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTMDVNMedivation recent weakness a buying opportunity, says UBS
Subscribe for More Information
January 22, 2015
16:15 EDTMDVNMedivation initiated with a Sector Perform at RBC Capital
Subscribe for More Information
09:16 EDTMDVNOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTMDVNMedivation up 1.2% after Phase 2 TERRAIN trial achieved primary endpoint
07:12 EDTMDVNMedivation phase 2 TERRAIN trial achieved primary endpoint
Subscribe for More Information
January 20, 2015
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use